Racial Differences in Detection of Glaucoma Using Retinal Nerve Fiber Layer Thickness and Bruch Membrane Opening Minimum Rim Width.

Am J Ophthalmol

From the Hamilton Glaucoma Center, Shiley Eye Institute, and the Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, California (N.W.E.-N., S.M., T.N., A.Y., L.M.Z., H.H., J.P., E.W., R.N.W.).

Published: February 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: To compare the sensitivities and specificities of the retinal nerve fiber layer thickness (RNFLT) and Bruch membrane opening minimum rim width (BMO-MRW) reference database-based criteria for detection of glaucoma in individuals of European descent (ED) and individuals of African descent (AD).

Design: Comparative diagnostic analysis by race METHODS: 382 eyes of 255 glaucoma patients (ED = 170, AD = 85) and 94 eyes of 50 healthy individuals (ED = 30, AD = 20) with global and sectoral RNFLT and BMO-MRW measured with Spectralis optical coherence tomography (OCT) were included. Six diagnostic criteria were evaluated: global measurement below the 5th or 1st percentile, ≥1 of the 6 sector measurements below the 5th or 1st percentile, and superotemporal (ST) and/or inferotemporal (IT) measurement below the 5th or 1st percentile. The sensitivities and specificities of these measurements for detection of glaucoma were compared using bootstrapping methods.

Results: ST and/or IT RNFLT below the 5th percentile has the best performance for detection of glaucoma among RNFLT classifications with a sensitivity (95% CI) of 89.5% (86.1, 92.5) and specificity of 87.2% (77.8, 95.1). In AD individuals, sensitivities of ST and IT RNFLT and BMO-MRW measurements below the 5th percentile criteria were lower than in ED individuals (RNFLT: 83.7% vs 92.5%, and BMO-MRW: 72.1% vs 88.5%, respectively), as well as specificities (AD RNFLT: 73.7% and BMO-MRW: 89.5% vs ED RNFLT: 96.4% and BMO-MRW: 98.2%, respectively).

Conclusions: RNFLT and BMO-MRW had consistently lower diagnostic performance in AD individuals compared with ED individuals. BMO-MRW criteria might fail to detect as many as one-third of eyes with glaucoma, specifically in AD individuals. With the current reference database, RNFLT, and especially BMO-MRW, criteria are not adequate for diagnosing glaucoma in AD individuals.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajo.2022.10.010DOI Listing

Publication Analysis

Top Keywords

detection glaucoma
16
rnflt bmo-mrw
16
glaucoma individuals
12
5th 1st
12
1st percentile
12
rnflt
10
bmo-mrw
9
individuals
9
retinal nerve
8
nerve fiber
8

Similar Publications

Purpose: To investigate hand function and eye drop instillation success in adults with and without glaucoma.

Design: Cross-sectional pilot study.

Subjects: Adults aged ≥ 65 years with glaucoma who use eye drops daily and adults aged 65+ without glaucoma who do not regularly use eye drops.

View Article and Find Full Text PDF

Prcis: Protocol 30-2 of Melbourne Rapid Fields, online computer perimetry, provides a portable, reliable, and patient-friendly alternative to Humphrey Field Analyzer 30-2 SITA fast protocol for Japanese all severity stages of glaucoma patients.

Purpose: Melbourne Rapid Fields (MRF) online computer perimetry is a web-browser-based software that offers white-on-white threshold perimetry using any computer. This study evaluates the perimetric results of 30-2 protocol from MRF performed using a laptop computer in comparison to Humphrey Field Analyzer (HFA).

View Article and Find Full Text PDF

To explore the role and mechanism of the hypoxia-inducible factor-1 (HIF-1) pathway in rat retinal precursor R28 cell injury caused by the (E50K) mutation. This experimental study was conducted from November 2023 to October 2024. The retinas of 18-month-old wild-type (WT) mice and normal tension glaucoma mice with the (E50K) mutation were extracted for proteomic analysis.

View Article and Find Full Text PDF

Objective: Laronidase is the first drug of enzyme replacement therapy approved for the treatment of mucopolysaccharidosis type I (MPS I). However, its adverse events (AEs) have not been investigated in real - world settings. The aim of this study was to investigate AEs associated with laronidase using the Food and Drug Administration Adverse Event Reporting System (FAERS).

View Article and Find Full Text PDF

Unlabelled: Standard Automated Perimetry (SAP) is the mainstay for monitoring glaucoma progression and has been accepted by the U.S. Food and Drug Administration (FDA) as a trial endpoint, but only under stringent criteria of ≥7 dB loss in five pre-specified test locations.

View Article and Find Full Text PDF